Influence of antidepressants on hemostasis

Figures & data

Figure 1. Diagrammatic representation of primary hemostasis. 5-HT, serotonin; vWF, von Willebrand factor; ADP, adenosine diphosphate; βTG, β-thromboglobulin; PF4, platelet factor 4; MLC, myosine light chain; MLCK, myosine light chain kinase; PGG₂, prostaglandin G2; PGH₂, prostaglandin H₂; PIP₂ phosphatidylinositol 3,4-bisphosphate; PKC, protein kinase C; P47, pleckstrin phosphoprotein; TK, tyrosine kinase; PECAM, platelet endothelial cell adhesion molecule; DAG, diacylglycerol; COX, cyclo-oxygenase Adapted from ref 21: Colman RW, Clowes AW, George JN, et al. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Fifth ed. Philadelphia, Pa: Lippincott Williams and Wilkins; 2006. Copyright © Lippincott, Williams and Wilkins 2006.

Table I. Laboratory tests of hemostasis. This list does not concern the third and fourth stages of hemostasis; the process is terminated by antithrombotic control mechanisms and fibrinolysis.

Table II. Clinical studies on modifications of hemostasis markers. DB, double-blind; PC, placebo-controlled; POC, prospective open comparative study; PO, prospective open; CS,cross-sectional; DEP, depression; SS, statistically significant; MAB, monoclonal antibodies; NA, non-available; IHD, ischemic heart disease; βTG, β-thromboglobulin; PF4, platelet factor 4; ANOVA, analysis of variance; PECAM, platelet endothelial cell adhesion molecule; 5-HT, serotonin; CI, confidence interval; PIT, platelet inositol triphosphate; LIBS, ligand-induced platelet binding site; aPTT, partial thromblastin time; INR, international normalized ratio; TT, thrombin time; AA, arachidonic acid; ADP, adenosine diphosphate; PT, prothtrombin time

Table III Case reports of modifications of hemostasis markers. AA, arachidonic acid; ADP, adenosine diphosphate; aPTT, partial thromboplastin time; INR, international normalized ratio

PollockBG.Laghrissi-ThodeF.WagnerWR.Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment.J Clin Psychopharmacol.20002013714010770450

 PubMed Web of Science ®Google Scholar

SerebruanyVL.GlassmanAH.MalininAI.et al.Endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) platelet substudy.Circulation.200310893994412912814

 PubMed Web of Science ®Google Scholar

SchinsA.HamulyakK.ScharpeP.et al.Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients.Life Sci.200424;76637650

 Web of Science ®Google Scholar

HergovichN.AignerM.EichlerHG.EntlicherJ.DruckerC.JilmaB.Paroxetine decreases platelet serotonin storage and platelet function in human beings.Clin Pharmacol Ther.20006843544211061584

 PubMed Web of Science ®Google Scholar

AlvarezJC.GluckD.ArnulfI.et al.Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine.Clin Pharmacol Ther.19996661762410613618

 PubMed Web of Science ®Google Scholar

MarkovitzJH.ShusterJL.ChitwoodWS.MayRS.TolbertLC.Platelet activation in depression and effects of sertraline treatment: an open-label study.Am J Psychiatry.20001571006100810831484

 PubMed Web of Science ®Google Scholar

Gomez-GilE.GastoC.CarreteroM.et al.Decrease of the platelet 5HT2A receptor function by long-term imipramine treatment in endogenous depression.Hum Psychopharmacol.20041925125815181653

 PubMed Web of Science ®Google Scholar

PiletzJE.ZhuH.MadakasiraS.et al.Elevated P-Selectin on platelets in depression: response tobupropion. J Psych iatr Res.200034397404

 PubMed Web of Science ®Google Scholar

MenysVC.SmithCC.LewinsP.FarmerRD.NobleMl.Platelet 5-hydroxytryptamine is decreased in a preliminary group of depressed patients receiving the 5-hydroxytryptamine re-uptake inhibiting drug fluoxetine.Clin Sci (Lond).9969187928774265

 PubMed Web of Science ®Google Scholar

Laine-CessacP.ShoaayI.GarreJB.GlaudV.TurcantA.AllainP.Study of haemostasis in depressive patients treated with fluoxetine.Pharmacoepidemiol Drug Saf.19987(suppl 1)S54S5715073961

 PubMed Web of Science ®Google Scholar

AldermanCP.SeshadriP.Ben-TovimDl.Effects of serotonin reuptake inhibitors on hemostasis.Ann Pharmacother.199630123212348913401

 PubMed Web of Science ®Google Scholar

TharmapathyP.SelheimF.OdegaardK.LundA.HolmsenH.Venlafaxine treatment stimulates blood platelet activity.J Clin Psychopharmacol.20002058959011001252

 PubMed Web of Science ®Google Scholar

LederbogenF.GillesM.MarasA.et al.Increased platelet aggregability in major depression?Psychiatry Res.20012425526111440776

 PubMedGoogle Scholar

LederbogenF.WeberB.CollaM.HeuserH.DeuschleM.DempfleCE.Antidepressant treatment and global tests of coagulation and fibrinolysis.J Clin Psychiatry.2001622

 Web of Science ®Google Scholar

BerkM.JacobsonBF.HurlyE.Fluoxetine and hemostatic function: a pilot study.J Clin Psychiatry.19955614167836333

 PubMed Web of Science ®Google Scholar

BangNU.Acquired abnormalities of platelet function [letter].N Engl J Med.199132416722030725

 PubMedGoogle Scholar

SerebruanyVL.GurbelPA.O'ConnorCM.Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors.Pharmacol Res.20014345346211394937

 PubMed Web of Science ®Google Scholar

MohammadSF.MasonRG.Inhibition of human platelet-collagen adhesion reaction by amitriptyline and impramine.Proc Soc Exp Biol Med.1974145110611134206514

 PubMed Web of Science ®Google Scholar

BondurantT.DarrellMJ.El AsyoutyS.et al.Effect of fluoxetine on prothrombin time.Psychosomatics.1998392962989664780

 PubMed Web of Science ®Google Scholar

AldermanCP.MoritzCK.Ben-TovimDl.Abnormal platelet aggregation associated with fluoxetine therapy.Ann Pharmacother.199226151715191482806

 PubMed Web of Science ®Google Scholar

De MaistreE.AllartC.LecompteT.BollaertPE.Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.Am J Med.200211353053212427509

 PubMed Web of Science ®Google Scholar

AranthJ.LindbergC.Bleeding, a side effect of fluoxetine.Am J Psychiatry.19921494121536285

 PubMed Web of Science ®Google Scholar

LeungM.ShoreR.Fluvoxamine-associated bleeding.Can J Psychiatry.1996416046058946088

 PubMed Web of Science ®Google Scholar

OttervangerJP.StriekerBH.HulsJ.WeedaJN.Bleeding attributed to the intake of paroxetine.Am J Psychiatry.19941517817828166328

 PubMed Web of Science ®Google Scholar

EvansTG.BuysSS.RodgersGM.Acquired abnormalities of platelet function [letter].N Engl J Med.19913241671

 Web of Science ®Google Scholar

HumphriesJE.WhebyMS.VandenbergSR.Fluoxetine and the bleeding time.Arch Pathol Lab Med.19901147277282363631

 PubMed Web of Science ®Google Scholar

CalhounJW.CalhounDD.Prolonged bleeding time in a patient treated with sertraline.Am J Psychiatry.19961534438610842

 PubMed Web of Science ®Google Scholar

CeylanME.Alpsan-OmayMH.Bleeding induced by SSRIs.Eur Psychiatry.20052057057116337893

 PubMed Web of Science ®Google Scholar

ThamCJ.TrewM.BragerN.Abnormal clotting and production of factor VIII inhibitor in a patient treated with venlafaxine.Can J Psychiatry.19994492392410584166

 PubMed Web of Science ®Google Scholar

DemetMM.MizrakS.Esen-DanaciA.Mirtazapine-induced arthralgia and coagulopathy: a case report.J Clin Psychopharmacol.20052539539616012290

 PubMed Web of Science ®Google Scholar

HardyJL.SiroisA.Reduction of prothrombin and partial thromboplastin times with trazodone.CMAJ.1986 1513513723779574

 PubMed Web of Science ®Google Scholar

TielensJA.Vitamin C for paroxetine - and fluvoxamine - associated bleeding.Am J Psychiatry.1997 1548838849167526

 PubMed Web of Science ®Google Scholar